SCHEMBL3605400

SCHEMBL3605400

CC(C)N(C(=O)C=Cc1nc(-c2ccc(F)cc2)cs1)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.43
ALDH1A1 P00352 5/20 0.43
NPC1 O15118 5/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
CAPN1 P07384 3/20 0.42
KMT2A Q03164 4/20 0.42
ALOX5 P09917 2/20 0.41
MEN1 O00255 3/20 0.41
MAPT P10636 3/20 0.41
MAPK1 P28482 4/20 0.40
RXFP1 Q9HBX9 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GRM1 Q13255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605399 1.00 RAB9A (0.43) RAB9AALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL3612022 0.80 ALDH1A1 (0.49) RAB9AALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL3612019 0.80 ALDH1A1 (0.49) RAB9AALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL3650974 0.79 RAB9A (0.51) RAB9AALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL3650972 0.79 RAB9A (0.51) RAB9AALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL3614967 0.76 RAB9A (0.48) RAB9AALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL3618951 0.76 ALDH1A1 (0.57) RAB9AALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL3618953 0.76 ALDH1A1 (0.57) RAB9AALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL3614966 0.76 RAB9A (0.48) RAB9AALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL3615585 0.74 ALDH1A1 (0.58) RAB9AALDH1A1NPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304438-B2 Heteroarylacrylamides and their use as pharmaceuticals SANOFI (FR) 2012-11-06 US disclosed
US-20100016272-A1 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-01-21 US disclosed
EP-2099753-A2 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-09-16 EP disclosed
EP-1939180-A1 Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase sanofi-aventis (FR) 2008-07-02 EP disclosed
WO-2008074413-A2 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE SANOFI-AVENTIS (FR) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016272-A1 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS NOS3, PTGIS, NOS1 RAB9A 1874/4885ALDH1A1 2657/4885NPC1 4260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.